在皮肤T细胞淋巴瘤中,ATF5通过PI3K/AKT/mTOR途径促进恶性T细胞的存活
Mengzhou Cao1,2,3, Pan Lai1,2,3, Xiangjun Liu1,2,3
1Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China.
Frontiers in immunology
|January 15, 2024
概括
激活转录因子5 (ATF5) 在皮肤T细胞淋巴瘤 (CTCL) 中过度表达,并促进瘤细胞的存活. 这一发现为CTCL病理学和潜在的治疗点提供了新的见解.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 皮肤T细胞淋巴瘤 (CTCL) 是一种涉及恶性T细胞的皮肤癌.
- 鉴定CTCL中的瘤特异性机制是具有挑战性的,因为恶性和正常T细胞之间的相似性.
- 转录失调是癌症发展和药物耐药性的关键因素.
研究的目的:
- 为了识别参与CTCL病理的瘤特异性转录因子.
- 阐明这种转录因子在CTCL进展和存活中的作用.
主要方法:
- 分析单细胞测序数据以识别恶性T细胞中差异表达基因 (DEGs).
- 在CTCL细胞系中使用lentivirus介导基因敲除的功能验证 (Myla,H9).
- 评估细胞存活率,瘤生长,细胞亡和细胞周期分布,以及RNA测序以获得机械洞察力.
主要成果:
- 发现激活转录因子5 (ATF5) 在恶性T细胞中过度表达.
- 在CTCL患者中,ATF5过度表达与较差的治疗反应相关.
- 通过PI3K/AKT/mTOR通路,ATF5促进恶性T细胞的存活,并赋予对内质网膜应激的抵抗力.
结论:
- 该研究确定了CTCL中ATF5的瘤特异性过度表达.
- 在CTCL中,ATF5在促进瘤细胞存活和耐药性方面发挥着至关重要的作用.
- 这些发现为CTCL病原体提供了新的见解,并建议ATF5作为潜在的治疗点.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Tumor Immunotherapy
527
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
527
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
The Extrinsic Apoptotic Pathway
6.4K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.4K


